ERBB2 and neoplasm: Consistent with these findings, the efficacy of checkpoint inhibition appears to be more pronounced in tumor cells with lower tumor-associated antigen (TAA) expression levels, such as MDA-MB-468, compared to those with higher TAA expression levels, such as A431-HER2 and SK-BR-3 cells.